Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$10.71M
Enterprise Value$14.85M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue23.10
Enterprise Value/Gross Profit-112.78
Enterprise Value/Ebitda-2.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Leverage And CapitalizationThe balance sheet shows materially lower leverage versus 2020–2022 and a sizable equity base in 2023–2025. Stronger capitalization extends operational runway, reduces short-term refinancing pressure and provides capacity to fund clinical or commercial milestones without immediate distress.
Chairman Increases Stake And Funds R&DThe chairman's private share purchases and direct S$300k investment into the LongevityBank unit signal insider conviction and add targeted R&D capital. This can accelerate product development in cord blood therapeutics and align management incentives with long-term value creation.
Clear Strategic Push For International GrowthRebranding the subsidiary for international expansion formalizes a cross-border growth strategy and supports joint ventures, medical tourism, and regional partnerships. A focused international arm can broaden market access and diversify revenue sources over the medium term.
Bears Say
Persistent Operating Cash BurnOperating and free cash flow have been negative each year and worsened in 2025, indicating the company relies on external funding to operate. Sustained cash burn raises execution risk, forces dilutive financing or asset sales, and limits ability to invest organically in R&D or commercialization.
Worsening Unit EconomicsThe income statement shows volatile, small revenues with margins deeply negative and gross profit turning negative in 2025. Deteriorating unit economics imply product or cost issues that threaten scalability and make sustainable profitability dependent on meaningful operational or commercial shifts.
Negative Returns And Dilution/financing RiskReturns remain negative with ROE consistently below zero, suggesting the balance sheet currently supports losses rather than shareholder returns. Management retains authority to issue new shares, so future financing to cover burn could dilute existing holders and affect long-term shareholder value.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $10.71M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Technical Analysis
Ownership Overview
34.84% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
64.93% Public Companies and
Individual Investors